7- hesham sait - gtd final new
TRANSCRIPT
![Page 1: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/1.jpg)
Hesham Sait 6th Medical student ,Faculty of medicine
King Abdulaziz University Hospital
![Page 2: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/2.jpg)
Disclosure
I have nothing to disclose.
![Page 3: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/3.jpg)
Gestational Trophoblastic Disease(GTD)
It is an abnormal condition of the ovum where there are partly degeneration and partly hyperplastic changes in the young chorionic villi, these result in the formation of small cysts of varying size.
![Page 4: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/4.jpg)
Gestational Trophoblastic Disease (GTD)
Pre-Malignant
Complete Mole
Partial Mole
Malignant
Invasive mole
Choriocarcinoma
Placental site trophoblastic tumorsSeckl et al Lancet 2000 and palmeiri et al Lancet 2005
![Page 5: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/5.jpg)
Worldwide incidence of molar pregnancy
Regions Incidence/1000 pregnancies
North America and Europe 0.5–1
Asia and Middle East 1–12
Saudi Arabia 0.94–2.2
South Africa 0.87–4.88
West Africa and Nigeria 1.26
![Page 6: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/6.jpg)
∗ To estimate the prevalence of (GTD) in the western region of Saudi Arabia.
∗ To evaluate the success of treatment and the effect of age and risk group on survival.
![Page 7: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/7.jpg)
∗ Retrospective Coherent study.
∗ All patients treated for GTD between January 2001and December 2010 were identified using KAUH data base.
∗ Medical record was reviewed for age, parity, clinical presentation and treatment outcome.
∗ Data entered in SPSS v20.
∗ Survival of patients with GTN were calculated using Kaplain Mayer Test and Cox Regression were used for independent variable.
∗ Patients with persistent disease were evaluated according to their clinical treatment outcomes.
∗ Ethical approval were obtained.
![Page 8: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/8.jpg)
Results
![Page 9: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/9.jpg)
Demographic data of patients (n = 122)Variable n
Age (years)Mean ± SD (range) 31.52 ± 10.8 (15–56)
ParityMedian (range) 3 (0–7)
Gestational age (weeks)Mean ± SD (Range) 12.42 ± 3.2 (4–22)
Pre-evacuation level of hCG<100,000 u/ml>100,000 u/ml
30 (25%)92 (75%)
Median follow-up(months)Range
2412–72
![Page 10: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/10.jpg)
![Page 11: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/11.jpg)
Number %
SuctionEvacuatio
n71 92.2
Hysterectomy
6 7.8
![Page 12: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/12.jpg)
Summary of patients who underwent hysterectomy as initial
treatment Case
Age (years)
Parity (n) Pathology
1 52 10 Complete mole
2 45 7 Complete mole
3 54 10 Complete mole
4 49 7 Complete mole
5 47 7 Complete mole
6 54 9 Complete mole
![Page 13: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/13.jpg)
Persistent GTD %
Partialmole
1 1.3
Complete mole
19 24.6
All 20 25.9
![Page 14: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/14.jpg)
Criteria used to diagnosed GTN
Plateauing of HCG level over at least three weeks.A 10% or greater rise in HCG for three or more values over at least two weeks.Persistent of HCG six months after molar evacuation.
![Page 15: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/15.jpg)
All had two more cycles after zero HCG
All had one more cycle after zero HCG
![Page 16: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/16.jpg)
![Page 17: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/17.jpg)
1st case: High risk GTN died 24 hours after admission to ICU because of respiratory failure.
2nd case: low risk died from RTA few years after initial treatment of Mtx.
3rd case: low risk died from chemotherapy toxicity thought to be high risk was treated with MAC.
![Page 18: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/18.jpg)
Kaplain Mayer Test Comparison Wilcoxon Test P=0.69 (N/S)
Over-all 5 year survival98%
![Page 19: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/19.jpg)
P=0.49
![Page 20: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/20.jpg)
∗ We report the first survival data for GTN in Saudi Arabia. However, the overall incidence of GTD in Saudi Arabia will be better defined by establishment of a GTD registry.
![Page 21: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/21.jpg)
Acknowledgment
• Prof. Khalid Sait• Dr. Nisren Anfnan• Prof. Basem Aldeek
![Page 22: 7- hesham sait - gtd final new](https://reader034.vdocuments.net/reader034/viewer/2022051300/58ef8c4a1a28ab03218b45b5/html5/thumbnails/22.jpg)
Thank You..